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Abstract
Background: There have been suggestions of an association between Chlamydia pneumoniae, chlamydial heat shock protein
(Ch-hsp) 60 and human heat shock protein (h-hsp) 60 infection sero-status and development of secondary cardiovascular events.
Patients with diabetes might be at higher risk since they are prone to infections. The objective of this study was to investigate
prospectively the role of Chlamydia pneumoniae (CP), chlamydial heat shock protein (Ch-hsp) 60 and a possible intermediate role
of human heat shock protein (h-hsp) 60 sero-status in the development of secondary cardiovascular disease (CVD) events in
patients with coronary heart disease (CHD) under special consideration of diabetes mellitus.
Methods: Patients aged 30–70 undergoing an in-patient rehabilitation program after acute manifestation of coronary heart
disease (International Classification of Disease, 9th Rev. pos. 410–414) between January 1999 and May 2000 in one of two
participating rehabilitation clinics in Germany were included in this analysis. Chlamydia pneumoniae (CP), chlamydial heat shock
protein (Ch-hsp) 60 and human heat shock protein (h-hsp) 60 status at baseline were measured by serum immunoglobulin G
and A antibodies. Secondary CVD events (myocardial infarction, stroke, and cardiovascular death) were recorded during a mean
follow-up period of 33.5 months (response = 87%).
Results: Among the 1052 subjects 37.4% and 39.3% were sero-positive to CP IgA and IgG respectively, 22.2% were sero-
positive to Ch-hsp 60 IgG and 8.4% were positive to h-hsp 60 IgG at baseline. During follow-up, secondary CVD events occurred
among 71 (6.8%) participants. Occurrence of a secondary CVD event was more common among CP (IgA) and CP (IgG) sero-
positive than among sero-negative patients (p-values 0.04 and 0.1, respectively). The risk of secondary CVD events was
increased among patients with both a positive CP sero-status and diabetes compared to infection negative, non-diabetic patients
and in general, sero-positivity added a hazard to diabetes. The interaction term between infection sero-status and diabetes was
not statistically significant. We were not able to show an intermediate role of human heat shock protein (h-hsp) 60 sero-status
in the development of secondary CVD events in patients with CHD.
Conclusion: Results from this cohort of 1052 patients with pre-existing CHD cannot exclude a possible moderate increase in
risk of secondary CVD events among patients with a positive infection sero-status. However, our study showed no intermediate
role of human heat shock protein (h-hsp) 60 sero-status in the development of secondary CVD events in patients with CHD.
Larger studies or meta-analysis of multiple studies are needed to address the interaction between infection sero-status and
diabetes with adequate power.
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Background
Chlamydia pneumoniae (CP) is an obligate intracellular
organism. Sero-positivity is low in early childhood (< 5
years), rising rapidly during school age such that at age 20
years approximately 50% of individuals will have detecta-
ble antibodies. Seroprevalence continues to rise, at a
slower pace, in adulthood and reaches 75% in the elderly
population [1]. The first description of the clinical presen-
tation of C. pneumoniae infection appeared in 1985 [2].
Chlamydia pneumoniae is one infectious agent that has
received particular attention as a potent atherogenic stim-
ulus. Correlative studies suggest a possible relationship
between atherosclerosis and CP infection [3,4]. Patholog-
ical studies have revealed the localization of CP in athero-
sclerotic lesions [5]. Several animal models have
suggested a causal role of CP in atherogenesis [6,7], how-
ever, the precise mechanism(s) by which CP promote
atherosclerosis still remains unclear.
Inflammation, infection and autoimmunity to human
heat shock protein 60 (h-hsp60) have emerged as novel
risk factors for coronary heart disease during the past dec-
ade. Heat shock proteins are a class of highly conserved
proteins produced by all organisms as a result of stress
and damage caused by, for instance, exposure to chemical
and environmental factors, inflammation and infections
[8]. Because of the high sequence homology between bac-
terial and human heat shock proteins, they have been pos-
tulated to be critical antigens in autoimmune diseases. In
particular, it has been proposed that the immune
response to microbial hsp60 may lead to autoimmunity
to h-hsp60 and by that means nourish the development
of atherosclerosis [9]. Because serum antibodies against
chlamydial hsp60 from subjects with atherosclerosis may
cross-react with human hsp60 and mediate endothelial
cytotoxicity, [10] it is suggested that humoral immune
reactions to hsp60s may play an important role in vascu-
lar endothelial injury, a key process in the early stages of
atherosclerosis.
Two independent groups have shown that an elevated
anti-human hsp60 antibody level is a risk factor for pri-
mary coronary atherosclerosis, especially when it is
present with Chlamydia pneumoniae infection [11,12].
Therefore, it is suggested that heat shock protein (h-hsp)
60 may serve as a possible link between Chlamydia pneu-
moniae infection and atherosclerosis [12,13]. Elevated lev-
els of h-hsp60 antibodies have also been reported in
human sera obtained from patients with atherosclerosis
[14]. In a recent study, Heltai and colleagues demon-
strated associations of acute myocardial infarction with
high levels of anti-h-hsp60 and anti-CP antibodies, these
being independent risk factors for primary CHD [15].
The role of heat-shock proteins in patients with prevalent
coronary heart disease on prognosis has been rarely inves-
tigated. Furthermore, despite the fact that patients with
diabetes are immuno-compromised, remain persistently
at risk for infectious complications and are prone to
develop accelerated atherosclerosis [16], there are few epi-
demiological studies available investigating a potential
interaction between chlamydial sero-markers of infection,
heat shock proteins and secondary cardiovascular disease
(CVD) events in diabetics.
In this study we are investigating prospectively the role of
Chlamydia pneumoniae, chlamydial heat shock protein 60
and a possible intermediate role of human heat shock
protein 60 sero-status in the development of secondary
CVD events in patients with coronary heart disease
(CHD) under special consideration of diabetes, also com-
paring the relationship between chlamydial sero-markers
of infection, heat shock proteins and secondary cardiovas-
cular disease (CVD) events in patients with diabetes with
those without.
In addition, the association of CP sero-status and serum
concentration of C-reactive protein (CRP) was explored,
as CRP is considered a main determinant of secondary
CVD events.
Methods
Study design and study population
All patients aged 30–70 years participating in an in-
patient rehabilitation program after acute coronary syn-
drome (International Classification of Disease, 9th Rev.
pos. 410–414) or after coronary artery revascularisation
between January 1999 and May 2000 in one of two partic-
ipating rehabilitation clinics in Germany (Schwabenland-
Klinik, Isny and Klinik am Südpark, Bad Nauheim) were
enrolled in the study. Germany has a very comprehensive
in-patient rehabilitation program and patients who were
hospitalized due to acute coronary syndrome (i.e. unsta-
ble angina and myocardial infarction) or coronary artery
revascularisation (i.e. coronary artery bypass grafting, cor-
onary angioplasty, stent implantation) have the possibil-
ity to undergo an in-patient rehabilitation program
(rehab) after discharge from the acute care hospital. The
aims of this 3-weeks program are the reduction of cardio-
vascular disease risk factors, improvement of health
related quality of life, and the preservation of the ability to
work (latter only if a subject was working at onset of dis-
ease otherwise prevention of nursing care). This in-patient
rehabilitation program begins approximately three weeks
after the acute coronary syndrome or the revascularisation
procedure but this time interval may be longer in some
cases. In the current study only patients who were admit-
ted within 3 months after the acute coronary syndrome or
revascularisation procedure were included.BMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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Follow-up was conducted one and three years after dis-
charge from in-patient rehabilitation. All subjects gave
written consent to the study. The study was approved by
the Ethics Boards of the Universities of Ulm and Heidel-
berg and of the medical associations of the states of
Baden-Wuerttemberg and Hessen.
Data collection
At the beginning of the in-patient rehab all subjects filled
out a standardized questionnaire containing sociodemo-
graphic information, smoking status and medical history,
including a history of a physician's diagnosis of diabetes
mellitus. In addition, information was taken from the
patients' hospital charts, and a blood sample was drawn
after overnight fast shortly before discharge.
Active follow-up was conducted one and three years after
discharge from the rehab clinic. At both times informa-
tion was obtained from patients via a mailed standardized
questionnaire. A standardized questionnaire regarding
cardiovascular disease events and treatment since dis-
charge from the in-patient rehabilitation clinic was also
obtained from the patient's primary care physician. If a
subject died during follow-up, the death certificate was
obtained from local Public Health authorities and the
main cause of death was coded according to the Interna-
tional Classification of Diseases (9th Revision).
Secondary cardiovascular disease (CVD) events were
defined as CVD being main cause of death, or a physi-
cian's diagnosis of a non-fatal myocardial infarction or
ischemic cerebrovascular event. For the analyses in this
study, only subjects with sero-status of Chlamydia pneumo-
niae (CP), chlamydial heat shock protein (Ch-hsp) 60 and
human heat shock protein (h-hsp) 60 and physician's
questionnaire at follow up were included. Among 1206
patients with coronary heart disease recruited at baseline,
follow-up information by physician's questionnaire or by
death certificate could be obtained for 1052 patients
(87%), of whom infection sero-status could be deter-
mined for 1030 (98%) patients for Chlamydia pneumoniae.
H-hsp 60 was available in 983 (93%) patients.
Laboratory analyses
Blood samples drawn before hospital discharge from the
rehab clinic were prepared and serum for serology was
stored at -80°C. Serum samples were analysed for Chlamy-
dia pneumoniae by using specific enzyme immunoassay for
the qualitative and semiquantitative detection of specific
IgG or IgA antibodies (Chlamdia pneumoniae-IgG-sELISA
medac and Chlamdia pneumoniae-IgA-sELISA medac,
medac diagnostika, Hamburg, Germany).
The sero-positivity for the semiquantitative analysis was
defined as cut-off index (sample optical density/cut-off)
and evaluated as titer. Cut-off index ≤ 1.1 was defined as
negative with titer < 1:50, cut-off index >1.1 and ≤ 1.8 was
defined as positive with titer 1:50, cut-off index >1.8 and
≤ 3.6 was defined as positive with titer 1:100, cut-off index
>3.6 and ≤ 7.2 was defined as positive with titer 1:200.
Serum samples were also analysed by using recombinant
enzyme immunoassays for chlamydial heat shock protein
60 (cHSP60-IgG-ELISA medac, medac diagnostika, Ham-
burg, Germany) and human heat shock protein 60 immu-
noglobulin G antibodies (hHSP60-IgG-ELISA medac,
medac diagnostika, Hamburg, Germany). Serum samples
were also analysed by using recombinant enzyme immu-
noassays for chlamydial heat shock protein 60 (cHSP60-
IgG-ELISA medac, medac diagnostika, Hamburg, Ger-
many) and human heat shock protein 60 immunoglobu-
lin G antibodies (hHSP60-IgG-ELISA medac, medac
diagnostika, Hamburg, Germany). Blood lipids were
measured by routine methods and CRP was measured
using a high sensitivity CRP (hsCRP) method (N latex
CRP mono, Dade Behring, Marburg, Germany). All labo-
ratory measures were done in blinded fashion.
Statistical analyses
We first described the study population according to basic
socioeconomic and medical characteristics. We then cal-
culated the prevalence of sero-positivity to CP, Ch-hsp60
and h-hsp60 at baseline in the whole study population
and in various age groups stratified for gender. We quan-
tified possible associations with age by a chi-square statis-
tic.
Furthermore, we described the incidence of secondary car-
diovascular disease (CVD) events (cardiovascular death,
myocardial infarction and stroke) and their combination
during follow up. The occurrence of fatal and non-fatal
CVD events during follow up according to sero-prevalence
of CP, Ch-hsp60 and h-hsp60 at baseline was analysed by
the life table method.
Finally, we used the Cox proportional hazards model to
assess a possible association of sero-positivity to CP, Ch-
hsp60 and h-hsp60 and diabetes (alone and in combina-
tion) at baseline with fatal and non-fatal CVD events dur-
ing follow up while adjusting for the following covariates:
age (years), gender (male, female), HDL-cholesterol (>40,
≤ 40 mg/dl), history of smoking (never, ever), alcohol
consumption within last 12 months (none, any), school
education (≤ 9 years, >9 years), marital status (married,
other), history of myocardial infarction (never, ever),
study centre (Bad Nauheim/Isny). Associations were
quantified by hazard ratios (HR) and their 95% confi-
dence interval (CI). In addition, a possible interaction
between CP, Ch-hsp60 and h-hsp60 sero-status and dia-
betes was assessed by introducing a product term of each
of the infection markers and history of diabetes in theBMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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adjusted model. In addition, age and gender adjusted geo-
metric mean values of CRP (which is considered as a fea-
ture of atherosclerosis) were calculated and compared
according to CP, Ch-hsp60 and h-hsp60 sero-status and
history of diabetes by means of General Linear Regression
methods. All analyses were carried out using the SAS soft-
ware package, version 8.2.
Results
Table 1 shows some basic characteristics of the entire
study population with coronary heart disease and of
patients with an additional history of diabetes (n = 199,
19.3%). Of the 1052 patients, 84.9% were male. The
mean age of the study group was 60.0 ± 7.9 years and
56.9% of participants were in the age group 60–70 years.
Almost all (97.8%) were of German nationality and
83.9% were married. About 58% reported a history of
myocardial infarction. About 40% of the subjects had
HDL-cholesterol levels ≥ 40 mg/dl and 17.6% of the
entire study population had a body mass index > 30 kg/
m2 while 27.6% of patients with an additional history of
diabetes had a body mass index > 30 kg/m2.
Table 2 outlines sero-prevalence of Chlamydia pneumoniae
(CP), chlamydial heat shock protein (ch-hsp) 60 and
human heat shock protein (h-hsp) 60 sero-status at base-
line in various age groups stratified by gender. Sero-posi-
tivity for CP IgA was 38.1% and 33.3% for males and
females respectively and for CP IgG, it was 39.2% and
39.7% for males and females respectively. Sero-positivity
for chlamydial heat shock protein (Ch-hsp) 60 (IgG) was
21.9% in males and 28.1% in females (overall 22.2%).
Sero-positivity for human heat shock protein (h-hsp) 60
(IgG) was (8.7%) in males and (7.3%) in females (overall
8.4%).
Table 3 shows the occurrence of fatal and non-fatal cardi-
ovascular disease events for the entire study population
Table 1: Sociodemographic and medical characteristics of patients with coronary heart disease (CHD) (n = 1052) and an additional 
history of diabetes at baseline (n = 199)
Characteristics Total: N % Additional history of diabetes: N %
Gender
Male 894 84.9 151 75.9
Female 158 15.0 48 24.1
Age (years) (µ, SD) 60.0 ± 7.9 60.9 ± 6.5
30–49 148 14.1 15 7.5
50–59 305 29.0 50 25.2
60–70 599 56.9 134 67.3
Nationality a
German 1028 97.8 195 98.0
Other 23 2.2 4 2.0
School education
≤ 9 years 625 59.4 132 66.3
> 9 years 427 40.6 67 33.7
Family status
Married 883 83.9 162 81.4
Other 169 16.1 37 18.6
Smoking
Current 48 4.6 8 4.0
Former 667 63.4 120 60.3
Never 337 32.0 71 35.7
Alcohol consumption
Any 790 75.1 131 65.8
None 262 24.9 68 34.2
Body mass index (kg/m2)b
< 25 282 26.8 35 17.6
25–30 584 55.5 109 54.8
> 30 182 17.6 55 27.6
HDL-cholesterol (mg/dl)
< 40 638 60.6 129 64.8
≥ 40 414 39.4 68 34.2
History of myocardial infarction 610 58.0 120 60.3
a = There was one missing value for variable nationality
b = There were four missing values for variable body mass indexBMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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and for patients with and without a history of diabetes.
During follow up (mean 33.5 months), 21 subjects suf-
fered a cardiovascular death, another 30 a non-fatal myo-
cardial infarction and 20 a non-fatal stroke, resulting in a
total of 71 secondary CVD events. CVD events in general
were higher in patients with an additional history of dia-
betes when compared to others.
Table 4 provides information on the occurrence of sec-
ondary CVD in relation to the sero-prevalence of CP, Ch-
hsp60 and h-hsp60. Results from qualitative analyses
showed that, for CP IgA, 8.8% sero-positive patients and
5.7% sero-negative patients had a secondary CVD event (p
= 0.04). For CP IgG, 8.4% sero-positive patients and 5.9%
sero-negative patients had a secondary CVD event (p =
0.1). In addition, results from quantitative analyses con-
sidering various levels of circulating antibodies of CP, Ch-
hsp60 and h-hsp60 and secondary CVD events, antibody
titers of < 1:50, 1:50–1:100 and ≥ 1:200 was not statisti-
cally significantly associated with secondary CVD events
(results not shown).
Table 5 shows results of multivariate analyses using Cox
proportional hazards model to assess the associations of
sero-positivity to CP, Ch-hsp60 and h-hsp60 at baseline
with secondary fatal and non-fatal CVD events during fol-
low up. For the crude, partially adjusted (age and sex) and
fully adjusted models, the hazard ratios (HR) for develop-
ing a secondary CVD event given a positive CP IgA titre at
baseline were 1.60 (95% CI 1.01–2.55), 1.60 (95% CI
1.00–2.54) and 1.46 (95% CI 0.90–2.36) respectively, for
CP IgG: 1.46 (95% CI 0.92–2.33), 1.44 (95% CI 0.91–
Table 2: Sero-prevalence of Chlamydia pneumoniae and heat shock proteins 60 in the various age groups
Male N(%) Female N(%) All N(%)
N = 1030 Chlamydia pneumoniae (IgA) positive
Age groups
30–49 45 (34.4) 7 (46.7) 52 (35.6)
50–59 104 (39.4) 9 (25.0) 113 (37.7)
60–70 184 (38.3) 36 (34.3) 220 (37.7)
p = 0.5 p = 0.8 P = 0.9
All 333 (38.1) 52 (33.3) 385 (37.4)
N = 1030 Chlamydia pneumoniae (IgG) positive
Age groups
30–49 41 (31.5) 6 (40.0) 47 (32.4)
50–59 109 (41.1) 13 (36.1) 122 (40.5)
60–70 193 (40.3) 43 (41.0) 236 (40.4)
p = 0.2 p = 0.9 p = 0.2
All 343 (39.2) 62 (39.7) 405 (39.3)
N = 1029 Chlamydia heat shock protein 60 
positive
Age groups
30–49 26 (20.0) 2 (13.3) 28 (19.3)
50–59 52 (19.7) 7 (19.4) 59 (19.7)
60–70 114 (23.8) 27 (25.7) 141 (24.1)
p = 0.4 p = 0.2 p = 0.2
All 192 (21.9) 36 (28.1) 228 (22.2)
N = 983 Human heat shock protein 60 positive
Age groups
30–49 13 (10.5) 1 (7.1) 14 (10.1)
50–59 22 (8.9) 5 (13.9) 27 (9.5)
60–70 37 (8.0) 5 (5.0) 42 (7.5)
p = 0.4 p = 0.2 p = 0.5
All 72 (8.7) 11 (7.3) 83 (8.4)BMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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2.30) and 1.39 (95% CI 0.87–2.23) respectively and for
ch-hsp60 IgG titre at baseline were 1.12 (95% CI 0.65–
1.93), 1.09 (95% CI 0.63–1.88) and 1.01 (95% CI 0.62–
1.85) respectively. In the latter model, in addition to
chlamydial heat shock protein, human heat shock protein
sero-status was included but there was no change in the
hazard ratio values (HR value for presence of h-hsp60 was
1.08 (95% CI 0.62–1.87) in the fully adjusted model. Fur-
thermore, the interaction terms between CP IgA, CP IgG
and Ch-hsp60 IgG sero-status and diabetes was not statis-
tically significant given the limited number of events (p =
0.60, p = 0.86, p = 0.46) respectively. Furthermore, analy-
ses from our quantitative data did not show any statisti-
cally significant association between levels of circulating
antibodies of CP, Ch-hsp60 and h-hsp60 and secondary
CVD events considering antibody titers of < 1:50, 1:50–
1:100 and ≥ 1:200 (results not shown).
Table 6 shows in a multivariate analysis results of the asso-
ciation of combinations of sero-positivity to Chlamydia
pneumoniae (CP), chlamydial heat shock protein (ch-hsp)
60 with history of diabetes and secondary CVD event. The
risk of secondary CVD events was highest among patients
with both a positive sero-status for CP IgA, CP IgG, Ch-
hsp60 and diabetes and in general, sero-positivity tenta-
tively increased the HRs of diabetes.
Furthermore, we found associations between CP IgA, CP
IgG sero-positivity and CRP levels at baseline after adjust-
ing for age and gender (geometric mean: CP IgA negative,
3.22 mg/L vs CP IgA positive, 3.98 mg/L, (p = 0.01)),
(geometric mean: CP IgG negative, 3.31 mg/L vs CP IgG
positive, 3.77 mg/L, (p = 0.07)). Our analyses also
showed no association between Ch-hsp60 IgG and CRP
levels at baseline after adjusting for age and gender.
Discussion
In this prospective study, we investigated the role of and
Chlamydia pneumoniae (CP), Chlamydia heat shock pro-
tein (Ch-hsp) 60 and a possible intermediate role of
human heat shock protein (h-hsp) 60 antibodies in the
development of secondary cardiovascular events in
patients with coronary heart disease (CHD) under special
consideration of diabetes mellitus. The results from this
study showed that the occurrence of a secondary CVD
event was more common among CP (IgA) and tentatively
CP (IgG) sero-positive than among sero-negative patients
in crude analysis. However, the associations and a possi-
ble interaction between the sero-status of these infections
and history of diabetes were not statistically significant
after multivariate adjustment for covariates. Although the
study clearly demonstrated an increased risk in develop-
ing a secondary CVD event among sero-positive patients
with a history of diabetes compared to sero-negative with-
out and sero-positivity adding a hazard to diabetes, it is
suggested that mainly diabetes was responsible for the
increased risk. Furthermore, this study showed that
human heat shock protein 60 (h-hsp60) is unlikely an
intermediate factor for developing secondary CVD events
in the population studied.
Chlamydia pneumoniae is one infectious agent that has
received particular attention as a potent atherogenic stim-
ulus. However, the question whether serological evidence
of prior infection with CP and the presence of Ch-hsp60
and h-hsp60 is associated with MI and CHD death
remains a source of controversy, as several prospective
studies have failed to demonstrate consistent associations
between the presence of IgG antibodies to CP and inci-
dent MI [17-19]. Examples of some studies that looked at
primary CVD events include a nested case-control study
Table 3: Cardiovascular disease (CVD) events during follow-up (mean 33.5 months) in patients with coronary heart disease at baseline 





Total DM no DM Total DM no DM
Cardiovascular 
death




30 6 24 2.9 3.7 3.2




71 24 47 6.8 13.1 6.4
DM: Patients with a history of diabetes
no DM: Patients without a history of diabetesBMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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conducted within the context of the Cardiovascular
Health Study [20]. Results showed that high-titer CP IgG
was associated with an increased risk of primary CHD
(OR 2.2, 95% CI, 1.1–4.4), whereas, a low to moderate CP
antibody titre showed a weak non-significant association
of IgG antibodies to CP with the risk of primary CHD
among the elderly (OR 1.1, 95% CI, 0.7 to 1.8). Further-
more, Haider and colleagues found CP infection, as evi-
denced by sero-positivity, not to be associated with
increased risk for primary CVD in the Framingham Heart
Study cohort: CP IgG (HR 0.91, 95% CI, 0.68–1.20) and
CP IgA (HR 0.65, 95% CI, 0.39–1.07) [21].
Further examples of the limited number of studies that
looked at CP sero-positivity and secondary CVD events
include a prospective study in the context of the Heart
Outcomes Prevention Evaluation (HOPE) Study. Their
study showed that among patients with pre-existing CVD,
neither CP IgG (adjusted HR, 0.87; 95% CI, 0.68–1.10)
nor CP IgA (adjusted HR, 1.10; 95% CI, 0.90–1.34) pre-
dicted cardiovascular events during the 4.5 years of fol-
low-up. [22]. Another prospective study evaluated the
effect of pathogens and pathogen burden on the risk of MI
or death among coronary artery disease (CAD) patients.
This study demonstrated that baseline prevalence of anti-
bodies directed against CP was not significantly associated
with development of secondary MI or CVD death in an
elderly cohort after a 3 years follow-up period. [19]. Fur-
thermore, Haim and colleagues evaluated the association
between previous exposure to CP and future coronary risk
in patients with CHD. This was a prospective nested case-
control design including patients from a trial study of bez-
afibrate for the treatment of CHD. Results showed that
mean titers of anti-CP antibodies (IgG and IgA) in the
baseline sera of 136 patients who had coronary events
during a mean follow-up period of 6.2 years were similar
with 136 age- and gender-matched controls from same
trial without subsequent coronary events. [23].
In addition, another study investigated the role of infec-
tions, autoimmunity and inflammation in atherosclero-
sis. They studied the joint effect of chronic Chlamydia
pneumoniae (CP) infection, persistently elevated human
heat-shock protein 60 (h-hsp60) antibodies and C-reac-
Table 4: Occurrence of fatal and non-fatal CVD events during follow up according to sero-prevalence of Chlamydia pneumoniae (CP), 
chlamydia heat shock protein (ch-hsp)60, human heat shock protein (h-hsp)60 and diabetes (DM)
N (Column%) Fatal and Non-Fatal CVD-
Events During Follow-up N 
(column %)
P-value a
CP – (IgA) (N = 1030)
negative 645 (62.6) 37 (5.7)
positive 385 (37.4) 34 (8.8) 0.04
Patients with DM (N = 199)
CP – (IgA)-negative 111 (55.8) 12 (10.8)
CP – (IgA)-positive 88 (44.2) 12 (13.6) 0.5
CP – (IgG)
negative 625 (60.7) 37 (5.9)
positive 405 (39.3) 34 (8.4) 0.1
Patients with DM (N = 199)
CP – (IgG)-negative 114 (57.3) 12 (10.5)
CP – (IgG)-positive 85 (42.7) 12 (14.1) 0.4
Ch-hsp60
negative 801 (77.8) 54 (6.7)
positive 228 (22.2) 17 (7.5) 0.7
Patients with DM (N = 199)
Ch-hsp60-negative 158 (79.4) 18 (11.4)
Ch-hsp60-positive 41 (20.6) 6 (14.6) 0.6
h-hsp60 (N = 983) b
negative 900 (91.6) 64 (7.1)
positive 83 (8.4) 4 (4.8) 0.4
Patients with DM (N = 199)
h-hsp60-negative 186 (93.5) 21 (11.3)
h-hsp60-positive 13 (6.5) 3 (23.1) 0.2
a = Log Rank test used only on patients with measured antibody sero-status
b = Only available in 983 CHD patientsBMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
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tive protein (CRP) on coronary risk. Results showed that,
compared with persistently low levels, the risk of coronary
events was 2-fold for persistently elevated IgA antibodies
to CP (OR, 1.96; 95% CI, 1.14–3.36) and also for IgA anti-
bodies to h-hsp60 (OR,2.11; 95% CI, 1.08–4.13). The
risks associated with elevated antibodies were much
higher when CRP was also elevated [24]. In a previous
study, Huittinen and colleagues showed that an elevated
level of IgA antibodies to h-hsp60 in baseline serum pre-
dicted the occurrence of coronary event several years later
[11]. Although CP, a common respiratory pathogen
throughout the world, has been associated with athero-
sclerosis, in the above mentioned study, this finding indi-
cated that elevated levels of CP antibodies were not alone
a significant risk factor for coronary events. Instead, a 7-
fold risk emerged when an elevated level of IgA antibodies
to CP in baseline serum was accompanied by factors
related to auto-immunity and inflammation, such as ele-
vated levels of h-hsp60 IgA antibodies and CRP. Although
hsCRP levels were associated with C. pneumoniae antibod-
ies in our study, elevated hsCRP levels of patients did not
have any type of joint effect in predicting secondary car-
diac event (data not shown). This is in accordance with
observations of others [25,26]. CRP may be a more mod-
est predictor of CHD in elderly subjects, especially if
already having CHD, than previously reported. The intake
of aspirin and statins may further attenuate the predictive
power for later events in patients with CHD.
Furthermore, all patients included in this study had an
acute cardiovascular event within last 3 months before
baseline. However, such an event may also reduce anti-
body titers, as has been shown for (h-hsp) 60 [27] and this
may partly explain the negative results for secondary
events in patients with prevalent CHD of our study.
The following limitations of our study should be consid-
ered. Although we had a large sample of patients with
CHD (over 50% with a MI), fatal-CVD events were rare in
this study population. This might be explained by the fact
that mortality of MI is highest within the pre- and early
hospital phase. As the acute events leading to diagnosis of
CHD or MI had occurred at least 3 weeks before inclusion
in this study, we were dealing with a selection of patients
with a better prognosis compared to a patient population
within the early phase of a newly diagnosed CHD. Fur-
thermore, not all patients of course are willing or able to
participate in a rehab program. This is another reason why
severely ill-patients are probably underrepresented in our
study sample. In addition, proof of chlamydial heat shock
protein 60 immunoglobulin G is genus specific and not
specific to C. pneumoniae, although the majority of anti-
bodies against chlamdial LPS are due to C. pneumoniae.
Although inflammation represents an important feature
in all stages of atherogenesis and its complications
[28,29], we could not demonstrate an association
between infection markers, sero-status and levels of CRP,
even after consideration of history of diabetes. This may
indicate, however, that another pathway might be of more
importance.
Despite the above mentioned limitations, results of our
study cannot exclude a possible moderate increase in risk
of secondary CVD events among patients with a positive
infection sero-status, however, they clearly indicate an
increased risk among diabetic patients. This study further
showed that h-hsp60 is unlikely an intermediate factor for
developing secondary CVD events considering mecha-
nisms involved in autoimmunity. Larger studies or meta-
analysis of multiple studies are needed to address the
interaction between infection sero-status and diabetes
with adequate power. Notwithstanding the need of fur-
Table 5: Association of sero-positivity to Chlamydia pneumoniae (CP), chlamydia heat shock protein (ch-hsp)60 with secondary fatal 
and non-fatal CVD events during follow up: Results of a multivariate analysis
HR (95% CI)
Crude Partially adjusted a Fully adjusted b
CP (IgA)
Negative 1ref 1ref 1ref
Positive 1.60 (1.01–2.55) 1.60 (1.00–2.54) 1.46 (0.90–2.36)
CP (IgG)
Negative 1ref 1ref 1ref
Positive 1.46 (0.92–2.33) 1.44 (0.91–2.30) 1.39 (0.87–2.23)
ch-hsp60
Negative 1ref 1ref 1ref
Positive 1.12 (0.65–1.93) 1.09 (0.63–1.88) 1.01 (0.62–1.85)
a = Adjusted for age and gender
b = Adjusted for age, gender, HDL-cholesterol, smoking, alcohol consumption, school education, marital status, history of myocardial infarction, 
study centre
(Test for interaction between diabetes and CP IgA (p = 0.60), CP IgG (p = 0.86) and ch-hsp60 (p = 0.46))BMC Cardiovascular Disorders 2006, 6:17 http://www.biomedcentral.com/1471-2261/6/17
Page 9 of 10
(page number not for citation purposes)
ther evidence from such studies, patients with diabetes are
at special risk for developing secondary CVD events and
should be a target group for preventive measures.
Conclusion
Results from this cohort of 1052 patients with pre-existing
CHD cannot exclude a possible moderate increase in risk
of secondary CVD events among patients with a positive
infection sero-status. However, our study showed no
intermediate role of human heat shock protein (h-hsp) 60
sero-status in the development of secondary CVD events
in patients with CHD. Larger studies or meta-analysis of
multiple studies are needed to address the interaction
between infection sero-status and diabetes with adequate
power.
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